查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456913

凝血分析儀市場－2024年至2029年預測

Coagulation Analyzer Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

凝血分析儀市場預計將以 5.91% 的複合年成長率成長，從 2022 年的 34.41 億美元增至 2029 年的 51.44 億美元。

凝血分析儀市場是指用於分析凝血過程的醫療設備的全球市場，凝血過程是人體形成血栓的自然能力。這些醫療設備主要用於診斷和監測與凝血障礙相關的疾病，例如血栓症、血友病和馮維勒布蘭德病。凝血分析儀利用光學、機械和電化學方法等多種技術來測量血液樣本中的凝血參數。測量的參數包括凝血時間、凝血酶原時間、活化部份凝血活酵素時間和國際標準化比率。

凝血疾病的盛行率不斷增加，以及用於診斷目的的凝血分析儀的需求不斷成長，是推動對這些解決方案的需求的關鍵因素。此外，自動凝血分析儀的採用和先進凝血檢測的市場開拓也有助於市場成長。凝血分析儀市場競爭激烈，大大小小的公司都在滿足廣泛的需求。這些公司提供各種凝血分析儀和相關產品，包括試劑、品管品和消耗品。此外，先進凝血分析新興市場的開拓和自動化凝血分析儀的採用預計將推動凝血分析儀市場的成長。與傳統手動方法相比，自動凝血分析儀具有更高的準確性、效率和速度。此外，先進凝血檢測的發展將使臨床醫生能夠準確有效地診斷和監測凝血障礙。

市場驅動力

  • 凝血障礙盛行率的上升正在推動市場成長。

血栓症、血友病和血管性血友病等凝血疾病的盛行率不斷增加，是凝血分析儀市場的主要驅動力。根據世界血友病聯合會的數據，全世界約有 40 萬人患有血友病，馮維樂布蘭氏症影響著全球約 1% 的人口。這些疾病的日益普及預計將推動對用於診斷目的的凝血分析儀的需求。

  • 老年人口增加推動市場擴張

人口老化也是凝血分析儀市場的主要促進因素之一。隨著年齡的成長，發生凝血障礙的風險會增加。根據美國統計，到2050年，全球65歲以上人口預計將達到15億，高於2019年的7.03億，比2015年增加2%。人口老化的加劇預計將在預測期內推動對凝血分析儀的需求。

  • 測試顯示凝血分析儀的需求預計將大幅成長

由於出血性疾病盛行率的增加、老年人口的增加以及對照護現場的需求的增加，用於血小板功能檢測的凝血分析儀的全球市場顯示出顯著的成長前景。血小板功能測試用於評估血小板形成血栓的能力，並已成為識別和治療各種出血性疾病的重要診斷工具。由於先進血小板功能檢測設備的發展、醫療保健支出的增加以及疾病早期診斷需求的增加，預計該市場將大幅成長。此外，在研究活動和臨床試驗中使用血小板功能測試預計將推動市場成長。

北美在全球凝血分析儀市場中佔有很大佔有率。

從地區來看，凝血分析儀市場分為北美、南美、歐洲、中東和非洲以及亞太地區。由於凝血障礙盛行率不斷增加、醫療保健成本不斷上升以及對先進凝血測試的需求不斷成長，預計北美凝血分析儀市場將在預測期內顯著成長。由於其領先的市場參與企業、成熟的醫療基礎設施和積極的政府舉措，美國預計將成為該地區的主要市場。

主要進展

  • 2021 年 7 月，Sysmex Europe 為歐洲、中東和非洲地區選定國家的大中型醫院和商業實驗室推出了兩款新型自動化凝血分析儀 CN-3500 和 CN-6500，現已上市。這些設備使用化學冷光酵素免疫分析法測定 (CLEIA) 在一台設備中測量各種血栓症和止血相關參數。這些設備能夠測量凝血的分子標記物，並記錄血栓性疾病的早期診斷和適當治療。 CN-3500和CN-6500採用整合方法進行止血測試，比使用多種不同測量原理的儀器的傳統方法更加複雜和耗時，提高了生產率、可靠性，並旨在提高可操作性和可維護性。
  • 2021年10月，領先的醫療設備Trivitron Healthcare與Diagon-Vanguard Diagnostics India合作，針對印度診斷領域推出了一系列新的凝血分析儀產品。 COAG 系列由匈牙利 Diagon 製造的自動、半自動和 POC 系統組成，可降低手術期間出血的風險，確定止血治療和抗凝血劑的有效性，並改善患者管理。這些凝血分析儀以其高通量和基於試劑的測試能力而聞名，從而提高了實驗室效率和周轉時間。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章凝血分析儀市場：依類型

  • 介紹
  • 半自動凝血分析儀
  • 全自動凝血分析儀
  • 其他

第6章 凝血分析儀市場：通過測試

  • 介紹
  • 纖維蛋白原測試
  • D-二聚體測試
  • 血小板功能測試
  • 其他

第7章凝血分析儀市場：依技術分類

  • 介紹
  • 光學技術
  • 機械技術
  • 電化學技術
  • 其他

第 8 章 凝血分析儀市場：依最終使用者分類

  • 介紹
  • 醫院
  • 診斷中心
  • 其他

第9章凝血分析儀市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • Roche
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthcare GmbH
  • Abbott
  • Beckman Coulter Diagnostics
  • Helena Laboratories Corporation
  • Meril Life Sciences Pvt. Ltd.
  • Trivitron Healthcare
  • Symex
簡介目錄
Product Code: KSI061614994

The coagulation analyzer market is projected to grow at a CAGR of 5.91% to reach US$5.144 billion in 2029 from US$3.441 billion in 2022.

The coagulation analyzer market refers to the global market for medical devices used to analyse the coagulation process, which is the body's natural ability to form blood clots. These devices are primarily used to diagnose and monitor conditions related to blood clotting disorders such as thrombophilia, hemophilia, and von Willebrand disease. Coagulation analyzers utilize various technologies, such as optical, mechanical, and electrochemical methods, to measure the coagulation parameters of a blood sample. The measured parameters include clotting time, prothrombin time, activated partial thromboplastin time, and international normalized ratio, among others.

The increasing prevalence of blood clotting disorders and the rising demand for coagulation analyzers for diagnostic purposes are the key factors driving the need for these solutions. Moreover, adopting automated coagulation analyzers and developing advanced coagulation assays are also contributing to the market growth. The coagulation analyzer market is highly competitive, with several large and small players catering to the wide demand. These players offer various coagulation analyzers and related products, such as reagents, controls, and consumables. Further, the development of advanced coagulation assays and the adoption of automated coagulation analyzers are expected to drive the growth of the coagulation analyzer market. Automated coagulation analyzers offer advantages over traditional manual methods, such as increased accuracy, efficiency, and speed. Moreover, developing advanced coagulation assays enables clinicians to accurately and efficiently diagnose and monitor blood clotting disorders.

Market Drivers

  • The rising prevalence of blood clotting disorders is propelling the market growth.

The increasing prevalence of blood clotting disorders such as thrombophilia, hemophilia, and von Willebrand disease is a major driver of the coagulation analyzer market. According to the World Federation of Hemophilia, approximately 400,000 people worldwide have hemophilia, while von Willebrand disease affects around 1% of the global population. The rising incidence of these disorders is expected to drive the demand for coagulation analyzers for diagnostic purposes.

  • The growing geriatric population has propelled the market expansion.

The aging population is another major driver of the coagulation analyzer market. As people age, their risk of developing blood clotting disorders increases. According to the United Nations, the global population aged 65 years and above is expected to reach 1.5 billion by 2050, up from 703 million in 2019, and the same source states, that the population aged 65years and above accounted for 10% of the global population, which signified a 2% increase over 2015's percent share. This increase in the aging population is expected to drive the demand for coagulation analyzers during the projected period.

  • Based on the test, the coagulation analyzer demand is expected to show significant growth

The global coagulation analyzer market for platelet function tests reveals significant growth prospects due to the increasing prevalence of bleeding disorders, the rising geriatric population, and the growing demand for point-of-care testing. Platelet function tests are used to evaluate the ability of platelets to form blood clots, making them an important diagnostic tool in identifying and managing various bleeding disorders. The market is expected to grow significantly due to the development of advanced platelet function testing devices, increasing healthcare expenditure, and the growing demand for early disease diagnosis. Using platelet function tests in research activities and clinical trials will also drive market growth.

North America accounted for a significant share of the global coagulation analyzer market.

Based on geography, the coagulation analyzer market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The North American coagulation analyzer market is expected to grow significantly during the projected period due to the increasing prevalence of coagulation disorders, rising healthcare expenditure, and growing demand for advanced coagulation testing. The United States is expected to be a significant market in this region due to major market players, well-established healthcare infrastructure, and favourable government initiatives.

Key Developments:

  • In July 2021, Sysmex Europe launched two new automated blood coagulation analyzers, the CN-3500 and CN-6500, for medium- to large-scale hospitals and commercial labs in select countries in the EMEA region. These devices use the chemiluminescence enzyme immunoassay (CLEIA) methodology to measure various thrombosis and hemostasis-related parameters with a single device. They can measure molecular markers for blood coagulation, offering early-stage diagnosis and appropriate treatment for thrombotic diseases. The CN-3500 and CN-6500 aim to improve productivity, reliability, operability, and serviceability for healthcare settings by using an integrated approach to hemostasis testing that is less complex and time-consuming than the traditional method, which uses multiple instruments with different measurement principles.
  • In October 2021, Trivitron Healthcare, a leading firm in medical devices, partnered with Diagon-Vanguard Diagnostics India to introduce a new series of Coagulation Analyzer products for the Indian diagnostics sector. The COAG Line comprises automated, semi-automated, and POC systems produced by Diagon Hungary to decrease bleeding risks during surgeries, determine the efficacy of hemostatic therapies and anticoagulant medicines, and improve patient management. These coagulation analyzers are widely known for their ability to test with high throughput and reagents, thereby increasing laboratory efficiency and turnaround time.

Segmentation:

By Type

  • Semi-Auto Coagulation Analyzer
  • Fully-Auto Coagulation Analyzer
  • Other

By Test

  • Fibrinogen Testing
  • D-Dimer Testing
  • Platelet Function Test
  • Others

By Technology

  • Optical Technology
  • Mechanical Technology
  • Electrochemical Technology
  • Others

By End User

  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. COAGULATION ANALYZER MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Semi-Auto Coagulation Analyzer
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness Insight
  • 5.3. Full-Auto Coagulation Analyzer
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness Insight
  • 5.4. Other
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness Insight

6. COAGULATION ANALYZER MARKET BY TEST

  • 6.1. Introduction
  • 6.2. Fibrinogen Testing
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness Insight
  • 6.3. D-Dimer Testing
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness Insight
  • 6.4. Platelet Function Tests
    • 6.4.1. Market Trends and Opportunities
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness Insight
  • 6.5. Others
    • 6.5.1. Market Trends and Opportunities
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness Insight

7. COAGULATION ANALYZER MARKET BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Optical Technology
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness Insight
  • 7.3. Mechanical Technology
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness Insight
  • 7.4. Electrochemical Technology
    • 7.4.1. Market Trends and Opportunities
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness Insight
  • 7.5. Others
    • 7.5.1. Market Trends and Opportunities
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness Insight

8. COAGULATION ANALYZER MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospital
    • 8.2.1. Market Trends and Opportunities
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness Insight
  • 8.3. Diagnostic Centers
    • 8.3.1. Market Trends and Opportunities
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness Insight
  • 8.4. Others
    • 8.4.1. Market Trends and Opportunities
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness Insight

9. COAGULATION ANALYZER MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Test
    • 9.2.3. By Technology
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Trends and Opportunities
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Trends and Opportunities
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Trends and Opportunities
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Test
    • 9.3.3. By Technology
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Trends and Opportunities
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Trends and Opportunities
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Trends and Opportunities
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Test
    • 9.4.3. By Technology
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Trends and Opportunities
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Trends and Opportunities
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. United Kingdom
        • 9.4.5.3.1. Market Trends and Opportunities
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Spain
        • 9.4.5.4.1. Market Trends and Opportunities
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Others
        • 9.4.5.5.1. Market Trends and Opportunities
        • 9.4.5.5.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Type
    • 9.5.2. By Test
    • 9.5.3. By Technology
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Trends and Opportunities
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. Israel
        • 9.5.5.2.1. Market Trends and Opportunities
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Trends and Opportunities
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Test
    • 9.6.3. By Technology
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Trends and Opportunities
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. Japan
        • 9.6.5.2.1. Market Trends and Opportunities
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Trends and Opportunities
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Trends and Opportunities
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Indonesia
        • 9.6.5.5.1. Market Trends and Opportunities
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Taiwan
        • 9.6.5.6.1. Market Trends and Opportunities
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Others
        • 9.6.5.7.1. Market Trends and Opportunities
        • 9.6.5.7.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Roche
  • 11.2. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 11.3. Siemens Healthcare GmbH
  • 11.4. Abbott
  • 11.5. Beckman Coulter Diagnostics
  • 11.6. Helena Laboratories Corporation
  • 11.7. Meril Life Sciences Pvt. Ltd.
  • 11.8. Trivitron Healthcare
  • 11.9. Symex